CTI BioPharma Competitors and Similar CompaniesClear all

CTI BioPharma's competitors and similar companies include Genoa Pharmaceuticals, Camurus, Antibe Therapeutics and JCR Pharmaceuticals.

	CTI BioPharma CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers.	Genoa Pharmaceuticals Genoa Pharmaceuticals develops therapies for the treatment of idiopathic pulmonary fibrosis.	Camurus Camurus is a research-based pharmaceutical company that develops medicines for severe and chronic conditions.	Antibe Therapeutics Antibe Therapeutics is a biotechnology company that specializes in the treatment of pain and inflammation.	JCR Pharmaceuticals JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products.
Founding Date	Founding Date 1992	Founding Date 2011	Founding Date 1991	Founding Date 2009	Founding Date 1975
Type	Type Public	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy
Locations	Locations Seattle, US HQ Köln, DE	Locations Seattle, US HQ	Locations Lund, SE HQ Sydney, AU Mannheim, DE Duxford, GB	Locations Toronto, CA HQ	Locations Ashiya, JP HQ Kobe, JP Kobe, JP Kobe, JP Kobe, JP
Employees	Employees 2546% decrease	Employees 1	Employees 265	Employees 44	Employees 934
Valuation ($)	Valuation ($) 1.2 b	Valuation ($) N/A	Valuation ($) 3.4 b	Valuation ($) 121.9 m	Valuation ($) 533.9 m
Financial
Revenue (est.)	Revenue (est.) $53.9m (FY, 2022)	Revenue (est.) N/A	Revenue (est.) kr2.3b (FY, 2025)	Revenue (est.) $7m (FY, 2023)	Revenue (est.) ¥33.1b (FY, 2025)
Cost of goods	Cost of goods $3.5m (FY, 2022)	Cost of goods N/A	Cost of goods kr138.7m (FY, 2025)	Cost of goods $3.9m (FY, 2023)	Cost of goods ¥8b (FY, 2025)
Gross profit	Gross profit $50.4m (FY, 2022)	Gross profit N/A	Gross profit kr2.1b (FY, 2025)	Gross profit $3m (FY, 2023)	Gross profit ¥25.1b (FY, 2025)
Net income	Net income ($93m) (FY, 2022)	Net income N/A	Net income kr735.6m (FY, 2025)	Net income ($19.5m) (FY, 2023)	Net income (¥4.7b) (FY, 2025)
Funding
Total funding raised	Total funding raised $ 105m	Total funding raised $ 64.2m	Total funding raised N/A	Total funding raised $ 6.2m	Total funding raised N/A